Stay updated on GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page.

Latest updates to the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page
- CheckyesterdayChange DetectedThe page's revision tag was updated from Revision: v3.6.2 to Revision: v3.6.3, indicating a newer release of the page. This is an internal version update and does not modify the study details or visible content.SummaryDifference0.1%

- Check8 days agoChange DetectedRevision tag updated from v3.6.0 to v3.6.2, indicating a deployment/patch update. No substantive study content or page details are affected.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedRecruitment status is updated to 'No longer looking for participants', signaling that enrollment for this study has closed. New help and navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study), and the Intervention/Treatment heading formatting was adjusted along with a release note for Revision: v3.6.0.SummaryDifference0.5%

- Check29 days agoChange DetectedThe page revision changed from v3.5.4 to v3.5.5, representing a minor update to the ClinicalTrials.gov page rather than a modification of the study data.SummaryDifference0.1%

- Check50 days agoChange DetectedThe site revision was updated from v3.5.3 to v3.5.4, indicating a new release of the platform. This update reflects backend or UI changes rather than modifications to the study details on the page.SummaryDifference0.1%

- Check72 days agoChange DetectedThe page’s displayed release/version indicator was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” indicating a minor site maintenance update rather than a change to the trial information.SummaryDifference0.1%

Stay in the know with updates to GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GRN-1201 & Pembrolizumab in Metastatic NSCLC Clinical Trial page.